VIDEO: Apellis plans to submit NDA for pegcetacoplan in first half of 2022

Issue: December 25, 2021

ByCedric Francois, MD, PhD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NEW ORLEANS — In this Healio Video Perspective from the Eyecelerator meeting, Cedric Francois, MD, PhD, Apellis co-founder and CEO, discusses study results and FDA communication regarding intravitreal pegcetacoplan for geographic atrophy.

Published by:

Sources/Disclosures

Collapse

Source: Cedric Francois, MD, PhD

Read more about

pegcetacoplan

fda

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

• Facebook
• Twitter
• LinkedIn
• Email
• Print
• Comment